Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.
Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia. In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures. Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive episodes caused by bipolar I disorder. Some off-label, unapproved uses of carbamazepine include the treatment of alcohol withdrawal syndrome and restless leg syndrome.
Pharmaceutical Research Association, Lenexa, Kansas, United States
King's College Hospital NHS Foundation Trust, London, United Kingdom
Whiston Hospital, Whiston, United Kingdom
Tameside Hospital, Manchester, United Kingdom
Clinical Pharmacology Unit, Merksem, Belgium
ASST Monza Ospedale San Gerardo, Monza, Italy
AP-HP Cochin, Paris, France
Stanford University, Palo Alto, California, United States
Christophe G Lambert, Albuquerque, New Mexico, United States
University of Maryland, Baltimore, Baltimore, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.